by Alwin L | Jan 27, 2026 | Ocaliva, Defective Drugs
Obeticholic Acid (Ocaliva®) and Hepatic Decompensation in Patients with Primary Biliary Cholangitis: Clinical Evidence, Regulatory Concerns, and Legal Implications Executive Summary AWKO is the lead United States law firm representing patients and families harmed by...
by Alwin L | Jan 26, 2026 | Ocaliva, Defective Drugs
Ocaliva (obeticholic acid) was developed to help people with Primary Biliary Cholangitis (PBC) protect their liver, but its side effects range from uncomfortable to life‑threatening, including liver failure in some patients. Understanding these risks empowers patients...
by Alwin L | Jan 12, 2026 | Ocaliva
Ocaliva (obeticholic acid) has helped many people manage Primary Biliary Cholangitis (PBC), but it also carries serious risks of liver damage that every patient and caregiver should understand. This AWKO guide breaks down five critical warning signs, what the FDA’s...
by Alwin L | Dec 29, 2025 | Ocaliva, Defective Drugs
The 2025 market withdrawal of Ocaliva (obeticholic acid) is one of the most significant developments PBC patients have faced in years, reshaping both treatment options and legal rights. This update from AWKO explains the full timeline, why the withdrawal matters for...
by Alwin L | Dec 15, 2025 | Ocaliva, Defective Drugs
Navigating the aftermath of a dangerous drug experience can be overwhelming, especially when it involves a once-promising medication like Ocaliva, prescribed to help people with primary biliary cholangitis (PBC). As hundreds, if not thousands, of Ocaliva lawsuits...
by Alwin L | Dec 8, 2025 | Ocaliva, Defective Drugs
Primary Biliary Cholangitis (PBC) is a chronic liver condition affecting thousands of patients across the United States. While new treatments offer hope, the tragic reality is that drugs like Ocaliva have brought severe risks and led many patients to seek legal...
